OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, et al.
Nature (2024) Vol. 627, Iss. 8004, pp. 646-655
Open Access | Times Cited: 35
Xiangnan Guan, Ruozhen Hu, Yoonha Choi, et al.
Nature (2024) Vol. 627, Iss. 8004, pp. 646-655
Open Access | Times Cited: 35
Showing 1-25 of 35 citing articles:
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 39
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 39
Regulatory T cells in immune checkpoint blockade antitumor therapy
An Zhang, Tao Fan, Yixiao Liu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
An Zhang, Tao Fan, Yixiao Liu, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma
Shreya Badhrinarayanan, Christopher Cotter, Huaqi Zhu, et al.
Future Oncology (2024) Vol. 20, Iss. 28, pp. 2049-2057
Open Access | Times Cited: 9
Shreya Badhrinarayanan, Christopher Cotter, Huaqi Zhu, et al.
Future Oncology (2024) Vol. 20, Iss. 28, pp. 2049-2057
Open Access | Times Cited: 9
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
Nicolas Roussot, Courèche Kaderbhaï, François Ghiringhelli
Cancers (2025) Vol. 17, Iss. 5, pp. 906-906
Open Access | Times Cited: 1
Nicolas Roussot, Courèche Kaderbhaï, François Ghiringhelli
Cancers (2025) Vol. 17, Iss. 5, pp. 906-906
Open Access | Times Cited: 1
Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints
Yunyan Dai, Chenyang Dong, Zhiming Wang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Yunyan Dai, Chenyang Dong, Zhiming Wang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Insights into the future of first-line advanced hepatocellular carcinoma treatment
Jeffrey Sum Lung Wong, Carmen Chak‐Lui Wong, Frances Sze Kei Sun, et al.
The Lancet Oncology (2025)
Closed Access
Jeffrey Sum Lung Wong, Carmen Chak‐Lui Wong, Frances Sze Kei Sun, et al.
The Lancet Oncology (2025)
Closed Access
Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and CD155/TIGIT Pathway
Jorge de la Torre Medina, Utsav Joshi, Himangshu Sonowal, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Jorge de la Torre Medina, Utsav Joshi, Himangshu Sonowal, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment
Wonjun Son, Yangsoon Lee, Yelim Park, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010728-e010728
Open Access
Wonjun Son, Yangsoon Lee, Yelim Park, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010728-e010728
Open Access
Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response
Li Liu, Peng Wu, Bingzhi Wang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Li Liu, Peng Wu, Bingzhi Wang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia
Yaoyao Wang, Xiancong Yang, Yalin Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Yaoyao Wang, Xiancong Yang, Yalin Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
New insights into cancer immune checkpoints landscape from single-cell RNA sequencing
Qian Wang, Jiahui He, Tianyu Lei, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025) Vol. 1880, Iss. 3, pp. 189298-189298
Closed Access
Qian Wang, Jiahui He, Tianyu Lei, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025) Vol. 1880, Iss. 3, pp. 189298-189298
Closed Access
Multi-omics in immunotherapy research for HNSCC: present situation and future perspectives
Xuan-Hao Liu, Guang-Rui Wang, Nian‐Nian Zhong, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Xuan-Hao Liu, Guang-Rui Wang, Nian‐Nian Zhong, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Stephen L. Wang, Timothy A. Chan
Cancer Cell (2025)
Closed Access
Stephen L. Wang, Timothy A. Chan
Cancer Cell (2025)
Closed Access
Applications of gene pair methods in clinical research: advancing precision medicine
Changchun Wu, Xuejun Xie, Xin Yang, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access
Changchun Wu, Xuejun Xie, Xin Yang, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access
CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy
Rosaely Casalegno‐Garduño, Alf Spitschak, Tim Pannek, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 930-930
Open Access
Rosaely Casalegno‐Garduño, Alf Spitschak, Tim Pannek, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 930-930
Open Access
Engineered platelet-derived exosomal spheres for enhanced tumor penetration and extended circulation in melanoma immunotherapy
Jian Zhao, Xinyan Lv, Lu Qi, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Jian Zhao, Xinyan Lv, Lu Qi, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)
Crescenzo D’Alterio, Giuseppina Rea, Maria Napolitano, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 6
Open Access
Crescenzo D’Alterio, Giuseppina Rea, Maria Napolitano, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 6
Open Access
The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy
Timothy R. McCulloch, Gustavo Rodrigues Rossi, Socorro Miranda‐Hernandez, et al.
Immunology and Cell Biology (2024) Vol. 102, Iss. 8, pp. 721-733
Closed Access | Times Cited: 3
Timothy R. McCulloch, Gustavo Rodrigues Rossi, Socorro Miranda‐Hernandez, et al.
Immunology and Cell Biology (2024) Vol. 102, Iss. 8, pp. 721-733
Closed Access | Times Cited: 3
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation
Katherine Nutsch, Karl L. Banta, Thomas D. Wu, et al.
Nature Cancer (2024)
Open Access | Times Cited: 3
Katherine Nutsch, Karl L. Banta, Thomas D. Wu, et al.
Nature Cancer (2024)
Open Access | Times Cited: 3
Metabolic reprogramming of macrophages in cancer therapy
Xudong Wang, Shaolong Zhang, Dixuan Xue, et al.
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 2
Xudong Wang, Shaolong Zhang, Dixuan Xue, et al.
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 2
Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection
Gabriela M. Webb, Cleiton Pessoa, Allyson J. McCullen, et al.
Journal of Virology (2024) Vol. 98, Iss. 6
Open Access | Times Cited: 2
Gabriela M. Webb, Cleiton Pessoa, Allyson J. McCullen, et al.
Journal of Virology (2024) Vol. 98, Iss. 6
Open Access | Times Cited: 2
Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations
Junwei Ge, Xuan Yin, Lujun Chen
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Junwei Ge, Xuan Yin, Lujun Chen
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy
Zhaokai Zhou, Jiaxin Xu, Shutong Liu, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 2
Zhaokai Zhou, Jiaxin Xu, Shutong Liu, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 2
Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review
Rui-Chen Xu, Yanwu Zhang, Cuicui Liu, et al.
The Lancet Regional Health - Western Pacific (2024), pp. 101180-101180
Open Access | Times Cited: 2
Rui-Chen Xu, Yanwu Zhang, Cuicui Liu, et al.
The Lancet Regional Health - Western Pacific (2024), pp. 101180-101180
Open Access | Times Cited: 2
A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives
Carlos Diego Holanda Lopes, Camila Bragança Xavier, Carlos Torrado, et al.
Journal of Immunotherapy and Precision Oncology (2024) Vol. 7, Iss. 4, pp. 283-299
Open Access | Times Cited: 2
Carlos Diego Holanda Lopes, Camila Bragança Xavier, Carlos Torrado, et al.
Journal of Immunotherapy and Precision Oncology (2024) Vol. 7, Iss. 4, pp. 283-299
Open Access | Times Cited: 2
